Antibacterial activity of telithromycin (HMR 3647) in relation to in vitro simulated human plasma kinetics | Zendy

Alain Bonnefoy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Antibacterial activity of telithromycin (HMR 3647) in relation to in vitro simulated human plasma kinetics

Author(s) -

Alain Bonnefoy

Publication year - 2001

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/47.4.471

Subject(s) - telithromycin , ketolide , streptococcus pneumoniae , erythromycin , haemophilus influenzae , microbiology and biotechnology , antibacterial agent , antibacterial activity , respiratory tract infections , medicine , antibiotics , biology , pharmacology , respiratory system , bacteria , genetics

Telithromycin (HMR 3647) is a ketolide suitable for the treatment of respiratory infections. The aim of this study was to demonstrate its antibacterial efficacy against an erythromycin-susceptible Staphylococcus aureus, an erythromycin-resistant Streptococcus pneumoniae and Haemophilus influenzae. The free serum concentrations of telithromycin, produced by repeated oral administration of 800 mg to adults for 10 days, was simulated in an in vitro system. The ketolide displayed bacteriostatic activity against all three strains tested. This study supported the observation that an 800 mg po dose of telithromycin demonstrated antibacterial efficacy against respiratory tract pathogens.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research